北里大学病院 呼吸器内科

Home

─ 研究実績 ─

2023

欧文原著論文

  1. The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer.
    Kasajima M, Igawa S, Manaka H, Yamada K, Akazawa Y, Manabe H, Yagami Y, Yamamoto H, Ito H, Kaizuka N, Nakahara Y, Sato T, Mitshufuji H, Yokoba M, Kubota M, Sasaki J, Naoki K.
    Oncology. 2023;101:69-76.
  2. Combination carboplatin and nab‑paclitaxel as a first‑line treatment for advanced thymic carcinoma.
    Manaka H, Igawa S, Yamamoto M, Oguri A, Manabe H, Kasajima M, Kusuhara S, Hosotani S,
    Nakahara Y, Sato T, Fukui T, Hisashi M, Sasaki J, Naoki K.
    Invest New Drugs. 2023 Feb;41(1):115-121. doi: 10.1007/s10637-023-01327-w. Epub 2023 Jan 12.
  3. Multicenter, single-arm phase II study of modified carboplatin/ nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426.
    Ichikawa Y, Seki N, Honda T, Sakugawa M, Hosokawa S, Bessho A, Agemi Y, Shimokawa T, Otani S, Nakahara Y, Naoki K,
    Yomota M, Hosomi Y, Takiguchi Y, Tokito T, Ando S, Okamoto H.
    Transl Cancer Res, 2023;12(4):873-886.
  4. Clinical roles of soluble PD‑1 and PD‑L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
    Himuro H · Nakahara Y, Igarashi Y, Kouro T, Higashijima N, Matsuo N, Murakami S, Wei F, Horaguchi S, Tsuji K, Mano Y, Saito H, Azuma K, Sasada T.
    Cancer Immunology, Immunotherapy, 2023;72:2829–2840.
  5. The Glasgow Prognostic Score Predicts Survival Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer.
    Igawa S, Yamamoto H, Yamada K, Akazawa Y, Manaka H, Yagami Y, Nakahara,Y, Sato T, Mitsufuji H, Sasaki J, Naoki K.
    Oncology, 2023;101:695–704
  6. Efects of Ephedra Herb extract on the expression of EGFR‑activating mutations and c‑Met in non‑small‑cell lung cancer cell line, H1975, and its combined efects with Osimertinib.
    Mori E, Hyuga S, Hanawa T, Naoki K, Odaguchi H,
    Journal of Natural Medicines, 2023;77:523–534.

2022

欧文原著論文

  1. Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexistin ginterstitial lung disease.
    Igawa S, Yokoba M, Takakura A, Hosotani S, Nakahara Y, Sato T, Mitsufuji H, Sasaki J, Naoki K.
    Invest New Drugs. 2022 40:182-189.
  2. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.
    Igawa S, Fukui T, Kasajima M, Ono T, Ozawa T, Kakegawa M, Kusuhara S, Sato T, Nakahara Y, Hisashi M, Sasaki J, Naoki K.
    Invest New Drugs. 2022. 40:430-437.
  3. Most Important Things and Associated Factors With Prioritizing Daily Life in Patients With Advanced Lung Cancer.
    Kameyama N, Sato T, Arai D, Fujisawa D, Takeuchi M, Nakachi I, Kawada I, Yasuda H,Ikemura S, Terai H, Nukaga S,Nakano Y, Hirano T, Minematsu N, Asakura T, Kamatani T, Tanaka K, Suzuki S, MiyawakiM, Naoki K, Fukunaga K, Soejima K.
    JCO Oncol Pract. 2022 Nov 8(12):1997-1986. DOI: 10.1200/OP.22.00124.
  4. A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small-Cell Lung Cancer: TORG1630.
    Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura Y, Kawashima Y, Furuya N, Shiraishi Y, Harada T, Tanaka H, Miura S, Uchiyama A, Nakahara Y, Tokito T, Naoki K, Bessho A, Goto Y, Seike M, Okamoto H.
    Clin Cancer Res. 2022 Aug 18:CCR-22-1687.
  5. Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring BRAF V600E Mutation.
    Yagami Y, Nakahara Y, Manabe H, Yamamoto H, Otani S, Sato T, Igawa S, Kubota M, Sasaki J, Naoki K.
    Onco Targets Ther. 2022 Nov 11;15:1369-1374.
  6. Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer .(OPEN/TORG2040) Fukui T, Sasaki J, Igawa S, Kada A, Saito TI, Kogure Y, Okamoto H, Naoki K.
    BMC Cancer. 2022 Dec 15;22(1):1314.
  7. Successful Tepotinib Challenge After CapmatinibInduced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report.
    Haraguchi MH , Sato T, Yamamoto H , Watanabe R , Kagyo J , Domoto H , Shiomi T.
    JTO Clinical and Research Reports , Vol. 3 No. 2: 100271.
  8. First‑line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non‑small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA
    John T , Sakai H , Ikeda S , Cheng Y , Kasahara K , Sato Y , Nakahara Y , Takeda M , Kaneda H ,
    Zhang H , Maemondo M , Minato K , Hisada T , Misumi Y , Satouchi M , Katsuyuki Hotta K , Li A , Oukessou A , Lu S.
    International Journal of Clinical Oncology (2022) 27:695–706.
  9. Pharmacokinetic and pharmacogenomic analysis of lowdose afatinib treatment in elderly patients with EGFR mutation-positive nonesmall cell lung cancer.
    Mizugaki H , Oizumi S , Fujita Y , Harada T , Nakahara Y , Takashina T , Ko R , Watanabe K , Hotta T ,
    Minemura H , Saeki K , Asahina H , Nakamura K , Nakamura H , Hosoda F , Yagishita S, Hamada A.
    European Journal of Cancer , 160 (2022) 227-234.
  10. Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy.
    Sinha A, Zou Y, Patel AS, Yoo S, Jiang F, Sato T, Kong R, Watanabe H, Zhu J, Massion PP, Borczuk AC, Powell CA.
    Cancers (Basel). 2022 Jan 29;14(3):708. doi: 10.3390/cancers14030708.
  11. Medical management of older patients with lung cancer.
    Zenke Y, Hakozaki T, Nakahara Y, Horinouchi H, Ohe Y;
    Lung Cancer Study Group of the Japan Clinical Oncology Group (JCOG).
    Jpn J Clin Oncol. 2022 Oct 6;52(10):1082-1088. doi: 10.1093/jjco/hyac135.PMID: 35975674 Review.
  12. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cance.
    Shirasawa M, Yoshida T, Imabayashi T, Okuma K, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Tsuchida T, Yamamoto N, Nakayama Y, Watanabe SI, Motoi N, Ohe Y.
    European Journal of Cancer 162 (2022) 1-10

2021

欧文原著論文

  1. A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncologyresearch group 1632.
    Noro R, Igawa S, Bessho A, Hirose T, Shimokawa T, Nakashima M, Minato K, Seki N, Tokito T, Harada T, Sasada S, Miyamoto S, Tanaka Y, Furuya N, Kaburagi T, Hayashi H, Iihara H, Okamoto H, Kubota K.
    Lung Cancer. 2021 Aug 31;161:49-54.
  2. Prognostic significance of galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy.
    Kusuhara S, Igawa S, Ichinoe M, Nagashio R, Kuchitsu Y, Hiyoshi Y, Shiomi K, Murakumo Y, Saegusa M, Satoh Y, Sato Y, Naoki K.
    Thorac Cancer. 2021 May;12(10):1570-1578.
  3. A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.
    Igawa S, Kasajima M, Ono T, Ozawa T, Kakegawa M, Kusuhara S, Sato T, Nakahara Y, Fukui T, Yokoba M, Kubota M, Mitsufuji H, Sasaki J, Naoki K.
    Cancer Management and Research. 2021:13 8695-8705.
  4. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial. [1]
    Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, OTANI S, Shimizu J, Katakami N, Azuma K, Miura N, Nishino K, Hara S, Teraoka S, Morita S, Nakagawa K, Yamamoto N.
    JAMA Oncol. 2021 Mar 1;7(3):386-394.
  5. Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement(WJOG9516L): A multicenter retrospective cohort study. [3]
    Ito K, Yamanaka T, Hayashi H, Hattori Y, Nishino K, Kobayashi H, Oya Y, Yokoyama T, Seto T, Azuma K, FUKUI T, Kozuki T, Nakamura A, Tanaka K, Hirano K, Yokoi T, Daga H, Sakata S, Fujimoto D, Mori M, Maeno K, Aoki T, Tamura A, Miura S, Watanabe S, Akamatsu H, Hataji O, Suzuki K, Hontsu S, Azuma K, Bessho A, Kubo A, Okuno M, Nakagawa K, Yamamoto N.
    Eur J Cancer. 2021 Mar;145:183-193.
  6. Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epiderm al growth factor receptor (TORG1320).
    Otani S, Sasaki J, Nakahara Y, Fukui T, Igawa S, Naoki K, Bessho A, Hosokawa S, Fukamatsu N, Nakamura Y, Kasai T, Sugiyama T , Tokito T, Seki N, Hamada A, Okamoto H, Masuda N.
    Invest New Drugs. 2021 Apr;39(2):530-536.
  7. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K, Otani S, Takeuchi S, Arai S, Nanjo S, Tanimoto A, Nishiyama A, Naoki K, Yano S.Cancer Sci. 2021.112:3784-3795.
  8. Implementation of clinical sequencing for molecular profiling in patients with advanced cancer.
    Fukui T, Sakai K, Sasaki J, Kakegawa MI, Igawa S, Mitsufuji H, Takeda M, Takahama T, Nakagawa K, Nishio K, Naoki K.
    Cancer Biomark. 2021.31:119-126.
  9. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer.
    Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, Ikemura S, Kawada I, Naoki K, Nakamura M, Ohtsuka T, Asamura H, Tsuchihara K, Hayashi Y, Hegab AE, Kobayashi SS, Kohno T, Watanabe H, Ornitz DM, Betsuyaku T, Soejima K, Fukunaga K.Cancer Res. 2021. 1:3916-3929.
  10. Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.
    Horiuchi K, Sato T, Kuno T, Takagi H, Hirsch FR, Powell CA, Fukunaga K.
    Lung Cancer. 2021. 156:59-67.
  11. Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study.
    Sato T, Fujisawa D, Arai D, Nakachi I, Takeuchi M, Nukaga S, Kobayashi K, Ikemura S, Terai H, Yasuda H, Kawada I, Sato Y, Satomi R, Takahashi S, Hashiguchi MH, Nakamura M, Oyamada Y, Terashima T, Sayama K, Saito F, Sakamaki F, Inoue T, Naoki K, Fukunaga K, Soejima K. Palliat Med. 2021. 35:943-951

欧文症例報告

  1. Standard therapy-resistant small cell lung cancer showing dynamic transition of neuroendocrine fate during the cancer trajectory: A case report.
    Ito F, Sato T, Emoto K, Kaizuka N, Yagi K, Watanabe R, Hashiguchi MH, Ninomiya H, Ikematsu Y, Tanaka K, Domoto H, Shiomi T.
    Mol Clin Oncol. 2021. 15:261.
  2. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
    Hashiguchi MH, Sato T, Watanabe R, Kagyo J, Matsuzaki T, Domoto H, Kato T, Nakahara Y, Yokose T, Hiroshima Y, Shiomi T.
    Thorac Cancer. 2021. 12:2504-2507.

2020

欧文原著論文

  1. Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.
    Igawa S, Ono T, Kasajima M, Manabe H, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K.
    Cancer Management and Research. 2020;12 :4911—4921.
  2. Impact of Neutrophil-To-Lymphocyte Ratio in Patients With EGFR-mutant NSCLC Treated With Tyrosine Kinase Inhibitors.
    Ono T, Igawa S, Kurahayashi S, Okuma Y, Sugimoto A, Kusuhara S, Ozawa T, Fukui T, Sasaki J,
    Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Naoki K.
    Invest New Drugs.2020;38:885-893.
  3. Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.
    Igawa S, Naoki K, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I , Kiura K, Takahashi K, Yamamoto N, Takiguchi Y, Miyaoka E, Okumura M, Yoshino I.
    Lung Cancer. 2020;146:160-164.
  4. The Clinical Impact of the Post-progression Survival on the Overall Survival in Elderly Patients or Those with a Poor Performance Status and Extensive-disease Small-cell Lung Cancer.
    Igawa S, Yokoba M, Fukui T, Sasaki J, Naoki K.
    Japanese Journal of Lung cancer 2020;60:10─16.
  5. TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma.
    Kuchitsu Y, Nagashio R, Igawa S, Kusuhara S, Tsuchiya B, Ichinoe M, Satoh Y, Naoki K, Murakumo Y, Saegusa M, Sato Y.
    Biomed Res. 2020;41:53-65.
  6. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
    Fukui T, Hosotani S, Soda I, Ozawa T, Kusuhara S, Kakegawa MI, Kasajima M, Hiyoshi Y, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Ishiyama H, Naoki K.
    Thorac Cancer. 2020;11:1005-1014.
  7. Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinoma.
    Nagashio R, Kuchitsu Y, Igawa S, Kusuhara S, Naoki K, Satoh Y, Ichinoe M, Murakumo Y, Saegusa M, Sato Y.
    Biomed Res.2020;41:149-159.
  8. Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.
    Igawa S, Ono T, Kasajima M, Kusuhara S, Otani S, Fukui T, Yokoba M, Kubota M, Katagiri M, Mitsufuji H, Sasaki J, Naoki K.
    Invest New Drugs. 38:1906-1914.2020
  9. Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells.
    Ohgino K, Terai H, Yasuda H, Nukaga S, Hamamoto J, Tani T, Kuroda A, Arai D, Ishioka K, Masuzawa K, Ikemura S, Kawada I, Nao ki K, Fukunaga K, Soejima K.
    Cancer Sci. 2020;111:3793-3801.
  10. Comparison between quantitative computed tomography, scintigraphy, and anatomical methods for prediction of postoperative FEV1 and DLCO: effects of chronic obstructive pulmonary disease status and resected lobes.
    Yokoba M, Ichikawa T, Harada S, Shiomi K, Mikubo M, Ono M, Sonoda D, Satoh Y, Hanawa H, Naoki K, Katagiri M.
    J Thorac Dis. 20 20;12:5269-5280.
  11. Serum immune modulators during the first cycle of anti-PD-1 antibody therapy in
    non-small cell lung cancer: Perforin as a biomarker. [1]
    Ota T, FUKUI T, Nakahara Y, Takeda T, Uchino J, Mouri T, Kudo K, Nakajima S, Suzumura T, Fukuoka M.
    Thorac Cancer. 2020 Nov;11(11):3223-3233.
  12. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial. [2]
    Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, NAKAHARA Y, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Hamada A, Yamada K, Okamoto H.
    JAMA Oncol. 2020 Jul 1;6(7):e201250.

2019

欧文原著論文

  1. Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study.
    Igawa S, Ono T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Yokoba M, Katagiri M, Naoki K.
    Cancer Manag Res. 2019;11:4883-4892.
  2. Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study.
    Ono T, Igawa S, Ozawa T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S,Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Katagiri M, Naoki K.
    Thorac Cancer. 2019;10(4):880-889
  3. Prognostic significance of G6PD expression and localization in lung adenocarcinoma.
    Nagashio R, Oikawa S, Yanagita K, Hagiuda D, Kuchitsu Y, Igawa S, Naoki K, Satoh Y, Ichinoe M, Murakumo Y, Saegusa M, Sato Y.
    Biochim Biophys Acta Proteins Proteom. 2019 1867:38-46.
  4. Clinicopathological and prognostic significance of nuclear UGDH localization in lung adenocarcinoma.
    Hagiuda D, Nagashio R, Ichinoe M, Tsuchiya B, Igawa S, Naoki K, Satoh Y, Murakumo Y, SAaegusa M, and Sato Y.
    Biomedical Research. 2019 40: 17-27.
  5. Questionnaire survey on patient awareness of invasive rebiopsy in advanced non-small cell lung cancer.
    Fukui T, Ishihara M, Kasajima M, Hiyoshi Y, Nakahara Y, Otani S, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.
    Thorac Cancer. 2019 ;10(3):501-507.
  6. Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
    Shirasawa M, Fukui T, Kusuhara S, Hiyoshi Y, Nakahara Y, Nishinarita N, Igawa S, Naoki K.
    BMC Cancer. 2019 Feb 20;19(1):163.
  7. Prognostic significance of IMMT expression in surgically-resected lung adenocarcinoma.
    Hiyoshi Y, Sato Y, Ichinoe M, Nagashio R, Hagiuda D, Kobayashi M, Kusuhara S, Igawa S, Shiomi K, Goshima N, Murakumo Y, Saegusa M, Satoh Y, Masuda N, Naoki K.
    Thorac Cancer. 2019;10:2142-2151.
  8. Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer.
    Shirasawa M, Fukui T, Kusuhara S, Harada S, Nishinarita N, Hiyoshi Y, Ishihara M, Kasajima M, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.
    PLoS One. 2019;14:e0214599.
  9. A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
    Tani T, Naoki K, Yasuda H, Arai D, Ishioka K, Ohgino K, Yoda S, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Soejima K.
    Cancer Chemother Pharmacol. 2019 Nov;84(5):1065-1071.
  10. Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017.
    Nakahara Y, Hosomi Y, Shibuya M, Mitsufuji H, Katagiri M, Naoki K, Soejima K, Nogami N, Nagase S, Nishikawa M, Minato K, Takiguchi Y, Seki N, Yamada K, Seto T, Okamoto H.
    Mol Clin Oncol. 2019 Oct;11(4):349-353.
  11. Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab.
    Oashi A, Yasuda H, Kobayashi K, Tani T, Hamamoto J, Masuzawa K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K, Soejima K.
    Mol Cancer Ther. 2019 Sep;18(9):1593-1601.
  12. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations.
    Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K, Ono F, Araki M, Kanada R, Ma B, Hayashi Y, Mimaki S, Yoh K, Kobayashi SS, Kohno T, Okuno Y, Goto K, Tsuchihara K, Soejima K.
    Proc Natl Acad Sci U S A. 2019 May 14;116(20):10025-10030.
  13. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study.
    Agemi Y, Shimokawa T, Sasaki J, Miyazaki K, Misumi Y, Sato A, Aida S, Ishii M, Nakamura Y, Naoki K, Okamoto H.
    PLoS One. 2019 Jan 17;14(1):e0210499.
  14. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
    Hasegawa H, Yasuda H, Hamamoto J, Masuzawa K, Tani T, Nukaga S, Hirano T, Kobayashi K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K, Soejima K.
    Lung Cancer. 2019 Jan;127:146-152.
  15. Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study.
    Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, Mitsufuji H, Kubota M, Hiyoshi Y, Ishihara M, Kasajima M, Sasaki J, Naoki K.
    Clin Lung Cancer. 2019 May;20(3):208-214.e2.

2018

欧文原著論文

  1. Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
    Igawa S, Shirasawa M, Ozawa T, Nishinarita N, Okuma Y, Ono T, Sugimoto A, Kurahayashi S, Sugita K, Sone H, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.
    Thorac Cancer. 2018 9:967-973.
  2. Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
    Sone H, Igawa S, Kasajima M, Ishihara M, Hiyoshi Y, Hosotani S, Ohe S, Ito H, Kaizuka N, Manaka H, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.
    Thorac Cancer. 2018 9:1279-1284.
  3. Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study.
    Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, Mitsufuji H, Kubota M, Hiyoshi Y, Ishihara M, Kasajima M, Sasaki J, Naoki K. Activity of Nivolumab and Utility of Clin Lung Cancer. 2018 S1525-7304(18)30103-7.
  4. Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Nishinarita N, Igawa S, Kasajima M, Kusuhara S, Harada S, Okuma Y, Sugita K, Ozawa T, Fukui T, Mitsufuji H, Yokoba M, Katagiri M, Kubota M, Sasaki J, Naoki K.
    Oncology. 2018;95:109-115.
  5. The role of prophylactic cranial irradiation for patients with small-cell lung cancer.
    Nakahara Y, Sasaki J, Fukui T, Otani S, Igawa S, Hayakawa K, Masuda N.
    Jpn J Clin Oncol. 2018 48:26-30.
  6. Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer.
    Igawa S, Otani S, Nakahara Y, Ryuge S, Hiyoshi Y, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sato Y, Sasaki J, Masuda N.
    Investigational New Drugs, 2018 36: 45-52.
  7. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S, Shirasawa M, Fukui T, Nishinarita N, Sone H, Ozawa T, Sugita K, Okuma Y, Kurahayashi S, Ono T, Sugimoto A, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.

    Oncology. 2018;94(4):207-214.
  8. Basigin expression as a prognostic indicator in stage I pulmonary adenocarcinoma.
    Matsumoto T, Nagashio R, Ryuge S, Igawa S, Kobayashi M, Fukuda E, Goshima N, Ichinoe M, Jiang SX, Satoh Y, Masuda N, Murakumo Y, Saegusa M, Sato Y.

    Pathol Int. 2018;68(4):232-240.
  9. Prognostic significance of S100A16 sub-cellular localization in lung adenocarcinoma.
    Kobayashi M, Nagashio R, Saito K, Aguilar-Bonavides C, Ryuge S, Katono K, Igawa S, Tsuchiya B, Jiang SX, Ichinoe M, Murakumo Y, Saegusa M, Satoh Y, Sato Y.

    Hum Pathol. 2018 Jan 7. [Epub ahead of print]
  10. Pharmacological and structural characterizations of naquotinib, a novel third generation EGFR tyrosine kinase inhibitor, in EGFR mutated non-small-cell lung cancer.
    Mol Cancer Ther. 2018 Feb 21.[Epub ahead of print] Hirano T, Yasuda H, Hamamoto J, Nukaga S, Masuzawa K, Kawada I, Naoki K, Niimi T, Mimasu S, Sakagami H, Soejima K, Betsuyaku T.
  11. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
    Ikeda S, Kato T, Ogura T, Sekine A, Oda T, Masuda N, Igawa S, Katono K, Otani S, Yamada K, Saito H, Kondo T, Hosomi Y, Nakahara Y, Nishikawa M, Utumi K, Misumi Y, Yamanaka T, Sakamaki K, Okamoto H. BMC Cancer. 2018;18(1):241.
  12. Prognostic significance of G6PD expression and localization in lung adenocarcinoma.
    Nagashio R, Oikawa S, Yanagita K, Hagiuda D, Kuchitsu Y, Igawa S, Naoki K,Satoh Y, Ichinoe M, Murakumo Y, Saegusa M, Sato Y.
    Biochim Biophys Acta. 2018 18:30072-4.
  13. Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer.
    Kobayashi K, Naoki K, Manabe T, Masuzawa K, Hasegawa H, Yasuda H, Kawada I, Soejima K, Betsuyaku T.
    Onco Targets Ther. 2018 :11:3335-3343.
  14. Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients.
    Yagasaki K, Komatsu H, Soejima K, Naoki K, Kawada I, Yasuda H, Hamamoto Y.
    Asia Pac J Oncol Nurs. 2018;5:172-177.
  15. Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease.
    Igawa S, Nishinarita N, Takakura A, Ozawa T, Harada S, Kusuhara S, Niwa H, Hosotani S, Sone H, Nakahara Y, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K.
    Cancer Manag Res. 2018;10:7013-7019
  16. Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer.
    Yanagita K, Nagashio R, Jiang SX, Kuchitsu Y, Hachimura K, Ichinoe M, Igawa S, Fukuda E, Goshima N, Satoh Y, Murakumo Y, Saegusa M, Sato Y.
    Am J Pathol. 2018 ;188:1328-1333.
  17. Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer.
    Shirasawa M, Fukui T, Kusuhara S, Hiyoshi Y, Ishihara M, Kasajima M, Nakahara Y, Otani S, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.
    Cancer Manag Res. 2018;21:6039-6047.

欧文症例報告

  1. A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation.
    Niwa H,Nakahara Y,Sasaki J,Masuda N.
    BMJ Case Rep.2018. pii: bcr-2017-219770.

2017

欧文原著論文

  1. Phase II Study of Amrubicin monotherapy in Elderly or Poor-risk Patients with Extensive Disease of Small Cell Lung Cancer.
    Igawa S, Otani S, Ryuge S, Fukui T, Nakahara Y, Hiyoshi Y, Mikiko Ishihara M, Kusuhara S, Harada S, Mitsufuji H, Kubota M, Sasaki J and Masuda N
    Invest New Drugs. 2017 35:642-648.
  2. Clinicopathological Significance of S100A14 Expressio in Lung Adenocarcinoma Ken Katono, Yuichi Sato, Makoto Kobayashi, Keita Saito, Ryo Nagashio, Shinichiro Ryuge, Satoshi Igawa, Hiroyasu Nakashima, Kazu Shiomi, Yukitoshi Satoh, Masaaki Ichinoe, Yoshiki Murakumo, Makoto Saegusa, Noriyuki Masuda Oncol Res Treat.
    2017, 2017 [Epub ahead of print]
  3. Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Igawa S, Ryuge S, Ichinoe M, Nakashima H, Otani S, Nakahara Y, Fukui T, Sasaki J, Kubota M, Katagiri M, Murakumo Y, Satoh Y, Sato Y, Masuda N.
    Oncol Res Treat. 2017;40:7-13.
  4. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
    Igawa S, Sato Y, Ryuge S, Ichinoe M, Katono K, Hiyoshi Y, Otani S, Nagashio R, Nakashima H, Katagiri M, Sasaki J, Murakumo Y, Satoh Y, Masuda N.
    Oncology. 2017;92:283-290
  5. Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy; relationship between nestin expression and epithelial to mesenchymal transition related markers.
    Ryuge S, Sato Y, Nagashio R, Hiyoshi Y, Katono K, Igawa S, Nakashima H, Shiomi K, Ichinoe M, Murakumo Y, Saegusa M, Satoh Y, Masuda N.
    PLoS One. 2017;12:e0173886
  6. Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status.
    Ishihara M, Igawa S, Sasaki J, Otani S, Fukui T, Ryuge S, Katono K, Hiyoshi Y, Kasajima M, Mitsufuji H, Kubota M, Yokoba M, Katagiri M, Sekiguchi A, Soda I, Ishiyama H, Hayakawa K, Masuda N.
    Oncol Lett. 2017:14:885-890.
  7. Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer.
    Kasajima M, Igawa S, Ishihara M, Otani S, Takakura A, Yokoba M, Kubota M, Sasaki J, Katagiri M, Masuda N.
    Oncol Lett. 2017; 13:1719-1724
  8. Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
    Misumi Y, Okamoto H, Sasaki J, Masuda N, Ishii M, Shimokawa T, Hosomi Y, Okuma Y, Nagamata M, Ogura T, Kato T, Sata M, Otani S, Takakura A, Minato K, Miura Y, Yokoyama T, Takata S, Naoki K, Watanabe K.
    BMC Cancer. 2017;17:377.
  9. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Okuma Y, Hosomi Y, Nakahara Y, Watanabe K, Sagawa Y, Homma S.
    Lung Cancer. 2017 ;104:1-6
  10. Complications after implantation of subcutaneous central venous ports (PowerPortⓇ).
    Nakamura T, Sasaki J, Asari Y, Sato T, Torii S, Watanabe M.
    Ann Med Surg (Lond). 2017;17:1-6.
  11. Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease.
    Niwa H, Nakahara Y, Yokoba M, Mitsufuji H, Sasaki J, Masuda N.

    Mol Clin Oncol. 2017;7:604-608

欧文症例報告

  1. Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature.
    Nakahara Y, Fukui T, Katono K, Nishizawa Y, Okuma Y, Ikegami M, Sasaki J, Masuda N.
    Case Rep Oncol. 2017 Apr 18;10(1):333-338.
  2. Pneumothorax during Pemetrexed Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report and Literature Review.
    Nakahara Y, Mikura S, Nagamata M, Fukui T, Sasaki J, Masuda N.
    Case Rep Oncol. 2017;10:428-432.

2016

欧文原著論文

  1. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.
    Igawa S, Sato Y, Ishihara M, Kasajima M, Kusuhara S, Nakahara Y, Otani S, Fukui T, Katagiri M, Sasaki J, Masuda N.
    Asian Pac J Cancer Prev. 2016;17:3249-53.
  2. Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer.
    Igawa S, Sasaki J, Otani S, Shirasawa M, Niwa H, Kusuhara S, Harada S, Kubota M, Katagiri M, Masuda N.
    Oncology. 2016;91:41-7.
  3. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
    Fukui T, Itabashi M, Ishihara M, Hiyoshi Y, Kasajima M, Igawa S, Sasaki J, Masuda N.
    BMC Cancer. 2016;16:197.
  4. Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1.
    Nakahara Y, Takagi Y, Hosomi Y, Kagei A, Yamamoto T, Sawada T, Yomota M, Okuma Y, Mikura S, Okamura T.
    Onco Targets Ther. 2016;9:5287-95.
  5. A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer.
    Okuma Y, Hosomi Y, Takahashi S, Nakahara Y, Watanabe K, Nagamata M, Takagi Y, Mikura S.
    Cancer Chemother Pharmacol. 2016;78:383-8.
  6. Predictive significance of thyroid transcription factor-1 expression in patients with non-squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib.
    Nakahara Y, Hosomi Y, Saito M, Ogawa M, Hishima T, Okamura T, Sasaki J, Masuda N.
    Mol Clin Oncol. 2016;5:14-8.
  7. Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
    Takagi Y, Hosomi Y, Nagamata M, Watanabe K, Takahashi S, Nakahara Y, Yomota M, Sunami K, Okuma Y, Shimokawa T, Okamura T.
    Cancer Chemother Pharmacol. 2016;77:559-64.
  8. Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis.
    Ebata T, Okuma Y, Nakahara Y, Yomota M, Takagi Y, Hosomi Y, Asami E, Omuro Y, Hishima T, Okamura T, Takiguchi Y.
    Thorac Cancer. 2016;7:39-43.
  9. Clinicopathological Significance of S100A10 Expression in Lung Adenocarcinomas.
    Katono K, Sato Y, Jiang SX, Kobayashi M, Saito K, Nagashio R, Ryuge S, Satoh Y, Saegusa M, Masuda N.
    Asian Pac J Cancer Prev. 2016;17:289-94.
  10. Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
    Hotta K, Sasaki J, Saeki S, Takigawa N, Katsui K, Takayama K, Nogami N, Shioyama Y, Bessho A, Kishimoto J, Tanimoto M, Kiura K, Ichinose Y.
    Clin Lung Cancer. 2016;17:75-9.

欧文症例報告

  1. Endobronchial involvement of mantle cell lymphoma: A case report.
    Katono K, Shirasawa M, Harada S, Niwa H, Nakahara Y, Igawa S, Yokoba M, Kubota M, Masuda N.
    Respir Med Case Rep. 2016, 19:77-9.
  2. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M, Kubotaa M, Harada S, Niwa H, Kusuhara S, Kasajima M, Hiyoshi Y, Ishihara M, Igawa S, Masuda N.
    Lung Cancer. 2016, 99:66-8.
  3. Endobronchial involvement of mantle cell lymphoma: A case report.
    Katono K, Shirasawa M, Harada S, Niwa H, Nakahara Y, Igawa S, Yokoba M, Kubota M, Masuda N.
    Respir Med Case Rep. 2016;19:77-9.
  4. Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer.
    Shirasawa M, Nakahara Y, Niwa H, Harada S, Ozawa T, Kusuhara S, Kasajima M, Hiyoshi Y, Sasaki J, Masuda N.
    Mol Clin Oncol. 2016;5:714-6.

2015

欧文原著論文

  1. Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group 0910.
    Yamada K, Saito H, Kondo T, Murakami S, Masuda N, Yamamoto M, Igawa S, Katono K, Takiguchi Y, Iwasawa S, Kurimoto R, Okamoto H, Shimokawa T, Hosomi Y, Takagi Y, Kishi K, Ohba M, Oshita F, Watanabe K.
    Anticancer Res. 2015;35:6705-11.
  2. Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.
    Igawa S, Sasaki J, Otani S, Ishihara M, Takakura A, Katagiri M, Masuda N.
    Oncology. 2015;89:275-80.
  3. Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
    Otani S, Hamada A, Sasaki J, Wada M, Yamamoto M, Ryuge S, Takakura A, Fukui T, Yokoba M, Mitsufuji H, Toyooka I, Maki S, Kimura M, Hayashi N, Ishihara M, Kasajima M, Hiyoshi Y, Katono K, Asakuma M, Igawa S, Kubota M, Katagiri M, Saito H, Masuda N.
    Am J Clin Oncol. 2015;38:405-10.
  4. Neurotoxicity due to prophylactic cranial irradiation for small-cell lung cancer: A retrospective analysis.
    Nakahara Y, Takagi Y, Okuma Y, Hosomi Y, Okamura T, Shibuya M, Masuda N.
    Mol Clin Oncol. 2015;3:1048-52.
  5. A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
    Yamada K, Aono H, Hosomi Y, Okamoto H, Kato T, Komase Y, Nishikawa M, Azuma K, Takeoka H, Okuma Y, Nakahara Y, Sato A, Oba MS, Morita S, Kunitoh H, Watanabe K.
    Eur J Cancer. 2015;51:1904-10.
  6. Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma.
    Yanagita K, Nagashio R, Ryuge S, Katono K, Jiang SX, Tsuchiya B, Nakashima H, Fukuda E, Goshima N, Saegusa M, Satoh Y, Masuda N, Sato Y.
    Asian Pac J Cancer Prev. 2015;16:7959-65.
  7. S100A16 is a Prognostic Marker for Lung Adenocarcinomas.
    Saito K, Kobayashi M, Nagashio R, Ryuge S, Katono K, Nakashima H, Tsuchiya B, Jiang SX, Saegusa M, Satoh Y, Masuda N, Sato Y.
    Asian Pac J Cancer Prev. 2015;16(:7039-44.
  8. Calnexin is a novel sero-diagnostic marker for lung cancer.
    Kobayashi M, Nagashio R, Jiang SX, Saito K, Tsuchiya B, Ryuge S, Katono K, Nakashima H, Fukuda E, Goshima N, Satoh Y, Masuda N, Saegusa M, Sato Y.
    Lung Cancer. 2015;90:342-5.
  9. Prognostic significance of MYH9 expression in resected non-small cell lung cancer.
    Katono K, Sato Y, Jiang SX, Kobayashi M, Nagashio R, Ryuge S, Fukuda E, Goshima N, Satoh Y, Saegusa M, Masuda N.
    PLoS One. 2015;10:e0121460.
  10. Diagnostic and prognostic significances of MUC5B and TTF-1 expressions in resected non-small cell lung cancer.
    Nagashio R, Ueda J, Ryuge S, Nakashima H, Jiang SX, Kobayashi M, Yanagita K, Katono K, Satoh Y, Masuda N, Murakumo Y, Hachimura K, Sato Y.
    Sci Rep. 2015;5:8649.
  11. Aminophylline increases respiratory muscle activity during hypercapnia in humans.
    Yokoba M, Ichikawa T, Takakura A, Ishii N, Kurosaki Y, Yamada Y, Tsukushi T, Masuda N, Easton PA, Katagiri M.
    Pulm Pharmacol Ther. 2015;30:96-101
  12. Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002.
    Sakata S, Sasaki J, Saeki S, Hamada A, Kishi H, Nakamura K, Tanaka H, Notsute D, Sato R, Saruwatari K, Iriki T, Akaike K, Fujii S, Hirosako S, Kohrogi H.
    Oncology. 2015;88:201-7.
  13. Ventilation and diaphragm activity during sustained hypoxia in awake canines.
    Fujimura N, Ji M, Jagers JS, Katagiri M, Easton PA.
    Respir Physiol Neurobiol. 2015 ;217:32-9.
  14. Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002.
    Sakata S, Sasaki J, Saeki S, Hamada A, Kishi H, Nakamura K, Tanaka H, Notsute D, Sato R, Saruwatari K, Iriki T, Akaike K, Fujii S, Hirosako S, Kohrogi H.
    Oncology. 2015;88:201-7.

欧文症例報告

  1. Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report.
    Igawa S, Yanagisawa N, Niwa H, Ishihara M, Hiyoshi Y, Otani S, Katono K, Sasaki J, Satoh Y, Masuda N.
    Oncol Lett. 2015;10:3519-3522.
  2. Pulmonary amyloidosis mimicking prostate cancer metastasis.
    Natsume S, Nakahara Y, Okamura T, Hishima T.
    Clin Case Rep. 2015;3:626-8.

2014

欧文原著論文

  1. Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation.
    Igawa S, Kasajima M, Ishihara M, Kimura M, Hiyoshi Y, Niwa H, Kusuhara S, Harada S, Asakuma M, Otani S, Katono K, Sasaki J, Masuda N.
    Cancer Chemother Pharmacol. 2014;74:939-46.
  2. Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
    Igawa S, Kasajima M, Ishihara M, Kimura M, Hiyoshi Y, Asakuma M, Otani S, Katono K, Sasaki J, Masuda N.
    Oncology. 2014;87:215-23.
  3. Circulating tumor cells as a prognostic factor in patients with small cell lung cancer.
    Igawa S, Gohda K, Fukui T, Ryuge S, Otani S, Masago A, Sato J, Murakami K, Maki S, Katono K, Takakura A, Sasaki J, Satoh Y, Masuda N.
    Oncol Lett. 2014 May;7(5):1469-1473.
  4. A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer.
    Takagi Y, Hosomi Y, Sunami K, Nakahara Y, Okuma Y, Yomota M, Shimokawa T, Nagamata M, Iguchi M, Okamoto H, Okamura T, Shibuya M.
    Oncologist. 2014;19:1194-9.
  5. Acquisition of useful sero-diagnostic autoantibodies using the same patients'sera and tumor tissues.
    Kobayashi M, Nagashio R, Ryuge S, Murakami Y, Yanagita K, Nakashima H, Matsumoto T, Jiang SX, Saegusa M, Satoh Y, Masuda N, Sato Y.
    Biomed Res. 2014;35:133-43.

欧文症例報告

  1. Successful chemotherapy with Carboplatin and s-1 for thymic carcinoma: a case report.
    Igawa S, Yanagisawa N, Ishihara M, Kimura M, Maki S, Otani S, Sasaki J, Masuda N.
    Case Rep Oncol. 2014;6:526-30
  2. Successful chemotherapy with nab-Paclitaxel in a heavily treated non-small cell lung cancer patient: a case report.
    Ishihara M, Igawa S, Maki S, Harada S, Kusuhara S, Niwa H, Otani S, Sasaki J, Jiang SX, Masuda N.
    Case Rep Oncol. 2014;7:401-6.